Titan Pharmaceuticals, Inc. (TTNP)
TTNP Stock Price Chart
Explore Titan Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze TTNP price movements and trends.
TTNP Company Profile
Discover essential business fundamentals and corporate details for Titan Pharmaceuticals, Inc. (TTNP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jan 1996
Employees
4.00
Website
https://www.titanpharm.comCEO
Weei Jye Chay
Description
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
TTNP Financial Timeline
Browse a chronological timeline of Titan Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 1 Jan 2026
Earnings released on 14 Aug 2025
EPS came in at -$0.65 .
Earnings released on 14 May 2025
EPS came in at -$0.62 .
Earnings released on 20 Mar 2025
EPS came in at -$0.85 , while revenue for the quarter reached $10.00K .
Earnings released on 3 Jan 2025
EPS came in at -$0.83 .
Earnings released on 15 Aug 2024
EPS came in at -$2.29 .
Earnings released on 15 May 2024
EPS came in at -$1.24 .
Earnings released on 1 Apr 2024
EPS came in at -$2.52 , while revenue for the quarter reached $81.00K .
Stock split effective on 9 Jan 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$0.40 , while revenue for the quarter reached $4.00K .
Earnings released on 14 Aug 2023
EPS came in at -$0.11 , while revenue for the quarter reached $1.00K .
Earnings released on 15 May 2023
EPS came in at -$2.20 , while revenue for the quarter reached $98.00K .
Earnings released on 31 Mar 2023
EPS came in at -$3.61 surpassing the estimated -$4.40 by +18.01%, while revenue for the quarter reached $51.00K .
Earnings released on 14 Nov 2022
EPS came in at -$3.60 surpassing the estimated -$4.20 by +14.29%, while revenue for the quarter reached $4.00K , missing expectations by -97.04%.
Earnings released on 11 Aug 2022
EPS came in at -$3.60 surpassing the estimated -$5.20 by +30.77%, while revenue for the quarter reached $150.00K , beating expectations by +11.11%.
Earnings released on 16 May 2022
EPS came in at -$4.80 , while revenue for the quarter reached $192.00K , beating expectations by +42.22%.
Earnings released on 25 Mar 2022
EPS came in at -$5.20 surpassing the estimated -$7.00 by +25.71%, while revenue for the quarter reached $135.00K , missing expectations by -88.02%.
Earnings released on 15 Nov 2021
EPS came in at -$3.80 falling short of the estimated -$0.35 by -985.71%, while revenue for the quarter reached $264.00K .
Earnings released on 16 Aug 2021
EPS came in at -$4.80 falling short of the estimated -$0.35 by -1.27K%, while revenue for the quarter reached $445.00K .
Earnings released on 17 May 2021
EPS came in at -$5.60 falling short of the estimated -$0.85 by -558.82%, while revenue for the quarter reached $682.00K , missing expectations by -33.49%.
Earnings released on 31 Mar 2021
EPS came in at -$0.86 surpassing the estimated -$1.33 by +35.34%, while revenue for the quarter reached $1.06M .
Stock split effective on 1 Dec 2020
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Nov 2020
EPS came in at -$30.03 falling short of the estimated -$24.02 by -25.02%, while revenue for the quarter reached $1.12M , beating expectations by +33.33%.
TTNP Stock Performance
Access detailed TTNP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.